Cyteir Therapeutics Inc

NASDAQ CYT

Download Data

Cyteir Therapeutics Inc Quick Ratio for the year ending December 31, 2023

Cyteir Therapeutics Inc Quick Ratio is NA for the year ending December 31, 2023. The quick ratio, also known as the acid-test ratio, measures a company's ability to meet its short-term obligations using its most liquid assets. It is calculated by dividing the current assets minus inventory by the current liabilities. This ratio provides insights into the company's liquidity position and its ability to pay off current liabilities without relying on inventory sales. A higher ratio suggests a stronger ability to meet short-term obligations with readily available assets.
  • Cyteir Therapeutics Inc Quick Ratio for the year ending December 31, 2021 was 25.71, a 561.43% change year over year.
  • Cyteir Therapeutics Inc Quick Ratio for the year ending December 31, 2020 was 3.89, a -73.73% change year over year.
  • Cyteir Therapeutics Inc Quick Ratio for the year ending December 31, 2019 was 14.80.
NASDAQ: CYT

Cyteir Therapeutics Inc

CEO Mr. Joseph S. Zakrzewski
IPO Date June 18, 2021
Location United States
Headquarters 128 Spring Street, Lexington, MA, United States, 02421
Employees 46
Sector Healthcare
Industry Biotechnology
Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Similar companies

MNOV

MediciNova Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

ELYM

Eliem Therapeutics Inc

NA

NA

HCWB

HCW Biologics Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email